Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología The therapeutic effects of Portulaca oleracea L. in hepatogastric disorders
Información de la revista
Vol. 42. Núm. 2.
Páginas 127-132 (Febrero 2019)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2171
Vol. 42. Núm. 2.
Páginas 127-132 (Febrero 2019)
Review
Acceso a texto completo
The therapeutic effects of Portulaca oleracea L. in hepatogastric disorders
Efectos terapéuticos de Portulaca oleracea L. en trastornos hepatogástricos
Visitas
2171
Tahereh Farkhondeha, Saeed Samarghandianb,
Autor para correspondencia
samarghandians1@nums.ac.ir

Corresponding author.
a Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
b Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. The gastro-protective and hepato-protective effects of Portulaca oleracea L.
Abstract
Aim

This research was conducted to obtain accurate information on the protective effects of Portulaca oleracea L. against hepatogastric diseases.

Results

P. oleracea L. (Purslane) has traditionally been used for the treatment of hepatogastric diseases. However, the low number of research studies has shown that P. oleracea L. possesses protective effects against hepatotoxic agents. The safety of P. oleracea L. has been demonstrated in several clinical trials.

Conclusion

Modern pharmacological studies have indicated the gastroprotective and hepatoprotective effects of P. oleracea L. by using in vivo and in vitro models. However, due to lack of information of its effects in humans, more studies should be conducted to confirm the efficacy of P. oleracea L. in humans.

Keywords:
Portulaca oleracea L.
Hepatoprotective
Gastroprotective
Inflammation
Oxidative stress
Resumen
Objetivo

Se realizó esta investigación para disponer de información precisa sobre los efectos protectores de Portulaca oleracea L. frente a enfermedades hepatogástricas.

Resultados

Portulaca oleracea L. (Purslane) se ha utilizado tradicionalmente para el tratamiento de enfermedades hepatogástricas. Sin embargo, las investigaciones limitadas han demostrado que Portulaca oleracea L. posee efectos protectores frente a sustancias hepatotóxicas. Varios ensayos clínicos han demostrado la seguridad de Portulaca oleracea L.

Conclusión

Estudios farmacológicos modernos han revelado los efectos gastroprotectores y hepatoprotectores de Portulaca oleracea L. mediante el uso de modelos in vivo e in vitro. Sin embargo, debido a la falta de información sobre sus efectos en el ser humano, se deben realizar más estudios para confirmar la eficacia de Portulaca oleracea L. en el ser humano.

Palabras clave:
Portulaca oleracea L.
Hepatoprotector
Gastroprotector
Inflamación
Agresión oxidativa
Texto completo
IntroductionGeneral

Portulaca oleracea L. (Portulaceae, common name purslane) is an annual herbaceous plant with reddish stems and alternate leaves from family Portulacaceae that is classified as a C4 plant.1 The plant is identified as one of the effective medicinal plants and named “Global Panacea” by the World Health Organization.1 Numerous pharmacological effects such as antioxidant, anti-inflammatory, and immunomodulatory activities have been found for P. oleracea L.2–6 It is also used as a vegetable, widely sold in shops in China, United Arab Emirates, and Oman.7P. oleracea L. presents variable chemical constituents, mainly belong to flavonoid, alkaloid, terpenoid, organic acid, and other natural compounds such as terpenoids, fatty acids, polysaccharides, sterols, vitamins, proteins, and minerals.8–10 Flavonoids are the main active constituents of P. oleracea L.11–13 The concentration of flavonoids in different plant parts are different. The highest amount is found in the root followed by stem and the leaf.14 Kaempferol, apigenin, luteolin, myricetin, and quercetin are major flavonoids in P. oleracea L.15P. oleracea L. prevents neurodegenerative disorders, coronary artery diseases, diabetes and its complications, respiratory failures, hepatic diseases, gastrointestinal diseases, and renal failures.16–18 Thus, the present study has been designed to provide an update review of the gastro-hepatoprotective effects of P. oleracea L.

Methods

Online literature resources have been checked using different search engines such as PubMed, Scopus, and Google Scholar to identify articles, editorials, and reviews about the gastroprotective and hepatoprotective effects of P. oleracea L. Hepatoprotective, P. oleracea L., gastroprotective, inflammation, and oxidative stress were selected as key words.

Gastroprotective effects

The aqueous and ethanolic extracts of P. oleracea L. (0.8–1.77g/kg) were inhibited gastric lesions induced by ethanol in mice. The findings have indicated that administration of extracts reduced the gastric acidity in pylorus-ligated mice.19 The gastroprotective effects of P. oleracea L. has been studied in acute gastric ulcer induced by aspirin, ethanol, cold restraint stress, as well as pyloric ligation and chronic ulcers induced by acetic acid in rats. P. oleracea L. (50–150mg/kg, PO) presented the significant protective effects against gastric ulcer. The study suggested that P. oleracea L. prevents the oxidative damage of gastric mucosa via increasing superoxide dismutase (SOD) and catalase (CAT) activities as well as decreasing lipid peroxidation. Additionally, P. oleracea L. decreased the acid and pepsin secretions and increased the synthesis of mucus.20

Hepatoprotective effectsProtective effects of P. oleracea L. against hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and also a leading cause of cancer-related death worldwide.21 The inflammatory cytokines and reactive oxygen species (ROS) play main roles in the initiation and progression of liver carcinogenesis.22–25 The anticancer effect of seed extracts of P. oleracea L. on the human hepatocellular carcinoma cells (HepG2) has been investigated.26 The results showed that P. oleracea L. decreases the cell viability of HepG2 in a dose dependent manner. The findings also indicated that P. oleracea L. decreases the adhesion capacity of HepG2 cells. The study has indicated the anticancer activity of P. oleracea against HepG2 cells, which may be used for the development of a potential therapeutic anticancer drug.26 The effects of P. oleracea L. against N-nitrosodiethylamine- (NDEA-) induced hepatocellular carcinomas (HCC) has also been investigated in mice. The results indicated that P. oleracea L. decreases the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in liver and serum. P. oleracea L. reduced the contents of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and malondialdehyde (MDA) as well as increased the activity of SOD in serum. P. oleracea L. attenuated the hepatic pathological changes. Treatment with P. oleracea L. inhibited the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), nuclear factor-kappa B (NF-κB), inhibitor of NF-κBα (IκBα) as well as up-regulated the expressions of NF-E2-related factor 2 (Nrf2) and heme oxygenase- (HO-) 1. The study suggested that P. oleracea L. has protective effects against NDEA-induced hepatocellular carcinoma by anti-inflammatory and antioxidative activities via the PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathways.27

Protective effects of P. oleracea L. against bile duct ligation (BDL)-induced hepatic fibrosis

Hepatic fibrosis is a major characteristic of many chronic liver diseases. The antioxidant effects of P. oleracea L. hydro-ethanolic extract against bile duct ligation-induced hepatic fibrosis have been investigated. Bile duct ligation increased liver enzymes, total bilirubin (TB), and TNF-α in serum along with the MDA level in liver tissues as well as decreased hepatic antioxidant defense system in rats. However, P. oleracea L. administration ameliorated all these alterations induced by BDL. The present study suggested that P. oleracea L. presents protective effects against cholestasis-induced liver fibrosis via inhibiting of oxidative stress and decreasing the expression of profibrogenic cytokines, collagenolytic activity as well as activation of hepatic stellate cells.28

Protective effects of Portulaca oleracea L. against hepatotoxic agentsCarbon tetrachloride

Carbon tetrachloride (CCl4) induces liver damage in animal models.29 Oxidative stress plays a main role in the progression of hepatic damage induced by CCl4. Additionally, the hepatotoxicity of CCl4 may be mediated by the indirect activation of Kupffer cells/macrophages and neutrophils.7 Kupffer cells induce the hepatic inflammation responses by generating TNF-α and other cytotoxic cytokines.30 CCl4 treatment increases inflammatory cascade by inducing the NF-κB pathway in the liver.31 Natural antioxidants are effective factors for preventing oxidative stress related liver diseases.32 The protective effect of P. oleracea L. ethanolic extract against carbon tetrachloride (CCl4)-induced hepatic toxicity has been investigated in rats. CCl4 increased serum activities of liver enzymes (ALT, AST, ALP, GGT) and decreased SOD level. CCl4 treatment induced histological alterations in the liver tissue. P. oleracea L. extract treatment ameliorated these alterations in CCl4-treated rats.21 The protective effect of the P. oleracea L. aqueous extract in combination with lycopene against CCl4 induced-hepatotoxicity has also been investigated in rats. Findings indicated that P. oleracea L. aqueous extract in combination with lycopene enhanced the hepatoprotective effect against CCl4 by ameliorating the levels of serum liver enzymes.33 The protective effects of ethanol extract of P. oleracea L. against CCl4-induced acute liver damage in mice have also been studied. The findings has indicated that P. oleracea L. treatment decreases the serum AST level and also the liver histological damage in mice. Nuclear translocation of p65 was enhanced in liver tissues of mice treated with P. oleracea. Furthermore, P. oleracea L. increased the NF-κB luciferase reporter gene activity and up regulated the level of phosphorylation of p65, but had no effects on mice liver SOD activity and MDA level in cultured hepatic cells. This study suggested that P. oleracea ameliorated CCl4 induced mice liver damage by enhancement of NF-κB activity.34

Cisplatin

Cisplatin (Cis), an anti-tumor drug, induces hepatotoxicity through induction of oxidative stress and inflammation.35,36 The protective role of aqueous extract of aerial parts of P. oleracea L. against cisplatin-induced hepatotoxicity in chick embryonic liver has been investigated. Cisplatin exposure increased ALT, AST, ALP, LDH and MDA levels and also decreased SOD, catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST) and reduced glutathione (GSH) in the rat liver tissue. It was found that P. oleracea L. prevents cisplatin-induced hepatotoxicity by ameliorating oxidative stress in rat liver.37

Acetaminophen

Acetaminophen (APAP) is an analgesic and antipyretic drug and long term use or over dosage of APAP may cause liver injury. N-acetyl-p-ben-zoquinone (NAPQI), an intermediate metabolite of APAP, binds to GSH and impairs the oxidant–antioxidant balance in hepatocytes.38,39 It was reported that the ethanolic extracts of P. oleracea L. prevented APAP-induced hepatotoxicity. The findings have indicated that P. oleracea L. reverse APAP induced hepatotoxicity by decreasing the ROS production in the liver of mice. In addition, P. oleracea L. administration decreased mice serum levels of IL-6 and TNFα and their mRNA expression in liver tissue. These findings have suggested that P. oleracea L. administration may be an effective against APAP-induced hepatotoxicity by ameliorating oxidative stress and inflammation responses.40

High fat diet

A high-fat diet is a major environmental factor that disturbed lipoprotein metabolism and is significantly associated with an increased prevalence of metabolic disorders.1,41 A high-fat/cholesterol diet increased oxidative stress in body contents.42 Natural antioxidants have been used to treat various metabolic diseases with no side effects.43 It was reported that P. oleracea L. prevents high-fat-diet-induced oxidative damage in mice liver. High-fat diet increased blood and liver lipid peroxidation level, and also decreased antioxidant enzymes activities in mice. Aqueous extract of P. oleracea L. decreased the levels of blood and liver MDA and increased the activities of blood and liver antioxidant enzymes activities in high fat mice. Additionally, aqueous extract of P. oleracea L. increased liver Leptin/β-actin (B), and Liver PPARα/β-actin, and also decreased liver, spleen FAS mRNA, p-PERK and p-PERK/PERK protein expression levels. These findings indicated that aqueous extract of P. oleracea L. ameliorated high fat diet-induced oxidative damage by increasing blood and liver antioxidant enzyme activities, modulating Leptin/β-actin (B), and Liver PPARα/β-actin, decreasing liver, spleen FAS mRNA, p-PERK and p-PERK/PERK protein expression levels in mice.44 The hepatoprotective effects of P. oleracea L. are presented in Table 1.

Table 1.

The gastro-protective and hepato-protective effects of Portulaca oleracea L.

  Experimental study  Mechanism  References 
POMice exposed to ethanol  Improved gastric lesions  19 
Rat exposed to aspirin, ethanol, cold restraint stress and acetic acid  Improved acute and chronic gastric ulcer by modulating oxidative stress  20 
HepG2  Decreased the cell viability, normal morphology and adhesion capacity of HepG2 cells  26 
Mice exposed to NDEA  Prevented hepatocellular carcinoma by anti-inflammatory and antioxidative activities via the PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathway  27 
BDL-induced hepatic fibrosis in rat  Inhibition of oxidative stress, decreasing the expression of profibrogenic cytokines, collagenolytic activity and activation of hepatic stellate cells  28 
Rat exposed to CCl4  In combination with lycopene enhanced the hepatoprotective effect against CCl4 by ameliorating the levels of serum liver enzymes  21,33 
Mice exposed to CCl4  Decreased the serum AST level and the liver histological damage, enhanced nuclear translocation of p65, increased the NF-κB luciferase reporter gene activity, up regulated the level of phosphorylation of p65  34 
Chick embryonic exposed to Cis  Prevented hepatotoxicity by ameliorating oxidative stress  37 
Mice exposed to APAP  Reversed APAP induced hepatotoxicity by decreasing the ROS production, decreased the serum levels of IL-6 and TNFα and their mRNA expression in liver, ameliorating inflammation responses and oxidative stress  33 
Mice fed high fat diet  Decreased the liver levels of MDA, liver FAS, p-PERK and p-PERK/PERK expression, increased the liver activities of antioxidant enzymes activities, liver Leptin/β-actin (B) and liver PPARα/β-actin  38 

Abbreviations – PO: Portulaca oleracea L., HepG2: hepatocellular carcinoma cells, NDEA: N-nitrosodiethylamine, PI3K: phosphatidylinositol 3 kinase, Akt: protein kinase B, mTOR: mammalian target of rapamycin, Nrf2: NF-E2-related factor 2, HO: heme oxygenase, NF-κB: nuclear factor-kappa B, BDL: bile duct ligation, CCl4: carbon tetrachloride, AST: aspartate aminotransferase, STZ: streptozotocin, CPOP: crude Portulaca oleracea L. polysaccharide, GTT:glucose tolerance test, FBG:fasting blood glucose, FINS: fasting serum insulin, ISI: insulin sensitivity index, TNF-α: tumor necrosis factor-α, IL-6: interleukin-6, MDA: methane dicarboxylic aldehyde,SOD: superoxygen dehydrogenises, Cis:Cisplatin, APAP: acetaminophen, FAS mRNA: fatty acid synthase mRNA, p-PERK: phospho-protein kinase RNA-like endoplasmic reticulum kinase, PPARα/β: peroxisome proliferator-activated receptor α/β.

Safety study

In vitro studies did not indicate the cytotoxic effects of P. oleracea L.45 Acute toxicity studies on the methanolic extract of P. oleracea L. in mice have indicated that P. oleracea L. is moderately toxic with LD50 value of 1853mg/kg. In the histopathologic studies, the methanolic extract have indicated hepatic and renal toxicities.46 According to the findings, P. oleracea L. has a high therapeutic index. However, more studies should be done on chronic toxicity of P. oleracea L. Most clinical trials have not indicated any adverse effects of P. oleracea L. However, thyroiditis, skin rash, facial nerve palsy have been found in three patients.47

Conclusion

In vitro and in vivo studies on P. oleracea L. have found that it has several biological activities such as gastro-protective and hepato-protective effects. According to the results of several studies, P. oleracea L. also acts as an antidote in hepatotoxicity induced by CCl4, Cis, APAP, and high-fat. In addition, P. oleracea L. has indicated the protective effects against hepatocellular carcinoma and hepatic fibrosis. These findings can help to produce hypothesis for therapeutic effects of P. oleracea L. which have to be confirmed by clinical trials. Clinical studies have indicated that oral dose of 180mg/day of the P. oleracea L. extract is safe and effective in the treatment of hypertension and hyperglycemia. Additionally, administration of P. oleracea L. (1g, orally) improved safely the psychological condition in chronic schizophrenic patients. Different mechanisms such as inhibition of oxidative stress, inflammation, and apoptosis are involved in the hepato-protective and gastro-protective effects of P. oleracea L. However, many pharmacological aspects of P. oleracea L. are yet to be studied. Therefore, the mechanisms of actions, clinical effectiveness, pharmacokinetic properties, and proper dosages should need to be further investigated.

Conflict of interest

The authors declare no conflict of interests.

References
[1]
R. Afshari, H. Hosseini, R. Khaksar, M.A. Mohammadifar, Z. Amiri, R. Komeili, et al.
Investigation of the effects of inulin and β-glucan on the physical and sensory properties of low-fat beef burgers containing vegetable oils: optimisation of the formulation using D-optimal mixture design.
Food Technol Biotechnol, 53 (2015), pp. 436-445
[2]
A. Ahangarpour, A.A. Oroojan, L. Khorsandi, R. Shabani, S. Mojaddami.
Preventive effects of betulinic acid on streptozotocin nicotinamide induced diabetic nephropathy in male mouse.
J Nephropathol, 5 (2016), pp. 128-133
[3]
K. Akamatsu, Y. Yamasaki, M. Nishikawa, Y. Takakura, M. Hashida.
Synthesis and phar-macological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(Lglutamic hydrazide) as a carrier.
Biochem Pharmacol, 62 (2001), pp. 1531-1536
[4]
S. Ali, M.M. Said, E.K. Hassan.
Prophylactic and curative effects of purslane on bile duct liga-tion-induced hepatic fibrosis in albino rats.
Ann Hepatol, 10 (2011), pp. 340-346
[5]
M. Anusha, M. Venkateswarlu, V. Prabhakaran, S. Shareen Taj, B. Pushpa Kumari, D. Ranga-nayakulu.
Hepatoprotective activity of aqueous extract of Portulaca oleracea in combination with lycopene in rats.
Indian J Pharmacol, 43 (2011), pp. 563-567
[6]
Y. Bai, Zang X. 2, Ma J. 3, G. Xu 4.
Anti-diabetic effect of Portulaca oleracea L. polysaccharide and its mechanism in diabetic rats.
pii: E1201.
[7]
S. Basu.
Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients.
Toxicology, 189 (2003), pp. 113-127
[8]
A.E. Abdel Moneim.
The neuroprotective effects of purslane (Portulaca oleracea) on rotenone-induced biochemical changes and apoptosis in brain of rat.
CNS Neurol Disord Drug Targets, 12 (2013), pp. 830-841
[9]
A.E. Abdel Moneim, M.A. Dkhil, S. Al-Quraishy.
The potential role of Portulaca oleracea as a neuroprotective agent in rotenone-induced neurotoxicity and apoptosis in the brain of rats.
Pestic Biochem Physiol, 105 (2013), pp. 203-212
[10]
S.I. Ali, M.M. Said, E.K. Hassan.
Prophylactic and curative effects of purslane on bile duct ligation-induced hepatic fibrosis in albino rats.
Ann Hepatol, 10 (2011), pp. 340-346
[11]
N. Sakai, K. Inada, M. Okamoto, Y. Shizuri, Y. Fukuyama.
Portuloside A, a monoterpene glucoside, from Portulaca oleracea.
Phytochem, 42 (1996), pp. 1625-1628
[12]
P. Salehi, B. Asghari, M.A. Esmaeili, H. Dehghan, I. Ghazi.
Glucosidase and amylase inhibitory effect and antioxidant activity of ten plant extracts traditionally used in Iran for diabetes.
J Med Plant Res, 7 (2013), pp. 257-266
[13]
Y.X. Zhou, H.L. Xin, K. Rahman, S.J. Wang, C. Peng, H. Zhang.
Portulaca oleracea L.: a review of phytochemistry and pharmacological effects.
Biomed Res Int, 2015 (2015), pp. 925631
[14]
H.B. Zhu, Y.Z. Wang, Y.X. Liu, Xia Yl, T. Tang.
Analysis of flavonoids in Portulaca oleracea L. by UV–vis spectrophotometry with comparative study on different extraction technologies.
Food Anal Methods, 3 (2010), pp. 90-97
[15]
K. Chan, M.W. Islam, M. Kamil.
The analgesic and antiinflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.).
Celak J Ethnopharmacol, 73 (2000), pp. 445-451
[16]
B.S. Chauhan, D.E. Johnson.
Seed germination ecology of Portulaca oleracea L.: an important weed of rice and upland crops.
Ann Appl Biol, 155 (2009), pp. 61-69
[17]
B. Chen, H. Zhou, W. Zhao, W. Zhou, Q. Yuan, G. Yang.
Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice.
Mol Biol Rep, 39 (2012), pp. 7981-7988
[18]
R.M. D’Andrea, C.S. Andreo, M.V. Lara.
Deciphering the mechanisms involved in Portulaca oleracea (C4) response to drought: metabolic changes including crassulacean acid-like metabolism induction and reversal upon re-watering.
Physiol Plant, 152 (2014), pp. 414-430
[19]
G. Karimi, H. Hosseinzadeh, N. Ettehad.
Evaluation of the gastric antiulcerogenic effects of Portulaca oleracea L. extracts in mice.
Phytother Res, 18 (2004), pp. 484-487
[20]
A. Kumar, A. Sharma, M. Vijayakumar, V. Rao Ch.
Antiulcerogenic effect of ethanolic extract of Portulaca oleracea experimental study.
Pharmacol Online, 1 (2010), pp. 417-432
[21]
A. Eidi, P. Mortazavi, J.Z. Moghadam, P.M. Mardani.
Hepatoprotective effects of Portulaca oleracea extract against CCl4-induced damage in rats.
Pharm Biol, 53 (2015), pp. 1042-1051
[22]
S. Samarghandian, M. Azimi-Nezhad, A. Borji, T. Farkhondeh.
Effect of crocin on aged rat kidney through inhibition of oxidative stress and proinflammatory state.
Phytother Res, 30 (2016), pp. 1345-1353
[23]
S. Samarghandian, M.A. Hadjzadeh, J.T. Afshari, M. Hosseini.
Antiproliferative activity and induction of apoptotic by ethanolic extract of Alpinia galanga rhizhome in human breast carcinoma cell line.
BMC Complement Altern Med, 14 (2014), pp. 192
[24]
Samarghandian S, Azimi-Nezhad M, Samini F, Farkhondeh T. Chrysin treatment improves diabetes and its complications in liver, brain, and pancreas in streptozotocin-induced diabetic rats Can J Physiol Pharmacol. 2016;94:388-93.
[25]
S. Samarghandian, M. Azimi-Nezhad, T. Farkhondeh, F. Samini.
Anti-oxidative effects of curcumin on immobilization-induced oxidative stress in rat brain, liver and kidney.
Biomed Pharmacother, 87 (2017), pp. 223-229
[26]
N.N. Farshori, E.S. Al-Sheddi, M.M. Al-Oqail, J. Musarrat, A.A. Al-Khedhairy, M.A. Siddiqui.
Cy-totoxicity assessments of Portulaca oleracea and Petroselinum sativum seed extracts on hu-man hepatocellular carcinoma cells (HepG2).
Asian Pac J Cancer Prev, 15 (2014), pp. 6633-6638
[27]
Z. Guoyin, P. Hao, L. Min, G. Wei, C. Zhe, L. Changquan.
Antihepatocarcinoma effect of Portulaca oleracea L. in mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathway.
Evid Based Complement Alternat Med, 2017 (2017), pp. 8231358
[28]
S.P. Thakare, H.N. Jain, S.D. Patil, U.M. Upadhyay.
Hepatoprotective effect of Cocculus hirsutus on bile duct ligation induced liver fibrosis in Albino Wistar rats.
Bangladesh J Pharmacol, 4 (2009), pp. 126-130
[29]
N. Mirazi, S.N. Movassagh, M. Rafieian-Kopaei.
The protective effect of hydro-alcoholic extract of mangrove (Avicennia marina L.) leaves on kidney injury induced by carbon tetrachloride in male rats.
J Nephropathol, 5 (2016), pp. 118-122
[30]
K. Akamatsu, Y. Yamasaki, M. Nishikawa, Y. Takakura, M. Hashida.
Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(l-glutamic hydrazide) as a carrier.
Biochem Pharmacol, 62 (2001), pp. 1531-1536
[31]
P. Schmiedeberg, L. Biempica, M.J. Czaja.
Timing of protooncogene expression varies in toxin-induced liver regeneration.
J Cell Physiol, 154 (1993), pp. 294-300
[32]
Hajzadeh MAR, Rajaei Z, Shafiee S, Alavinejhad A, Samarghandian S, Ahmadi M. Effect of barberry fruit (Berberis Vulgaris) on serum glucose and lipids in streptozotocindiabetic rats. Pharmacologyonline 2011;1:809-17.
[33]
M. Anusha, M. Venkateswarlu, V. Prabhakaran, S. Shareen Taj, B. Pushpa Kumari, D. Ranganayakulu.
Hepatoprotective activity of aqueous extract of Portulaca oleracea in combination with lycopene in rats.
Indian J Pharmacol, 43 (2011), pp. 563-567
[34]
H. Shi, Liu, G. Tang, H. Liu, Y. Zhang, B. Zhang, et al.
Ethanol extract of Portulaca oleracea L. reduced the carbon tetrachloride induced liver injury in mice involving enhancement of NF-κB activity.
Am J Transl Res, 6 (2014), pp. 746-755
[35]
L. Mahmoodnia, K. Mohammadi, R. Masumi.
Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient.
J Nephropathol, 6 (2017), pp. 144-149
[36]
Z. Pezeshki, A. Khosravi, M. Nekuei, S. Khoshnood, E. Zandi, M. Eslamian, et al.
Time course of cisplatin-induced nephrotoxicity and hepatotoxicity.
J Nephropathol, 6 (2017), pp. 163-167
[37]
D. Sudhakar, R. Krishna Kishore, P.R. Parthasarathy.
Portulaca oleracea L. extract ameliorates the cisplatin-induced toxicity in chick embryonic liver.
Indian J Biochem Biophys, 47 (2010), pp. 185-189
[38]
S.M. Mansouripour, R. Afshari.
Chlordiazepoxide preventive effect on tramadol overdose induced serotonin syndrome evaluated by hunter and radomski criteria: a clinical trial.
Toxicol Int, 20 (2013), pp. 126-131
[39]
H. Jaeschke, M.L. Bajt.
Intracellular signaling mechanisms of acetaminophen-induced liver cell death.
Toxicol Sci, 89 (2006), pp. 31-41
[40]
X.F. Liu, C.G. Zheng, H.G. Shi, G.S. Tang, W.Y. Wang, J. Zhou, et al.
Ethanol extract from Portulaca oleracea L. attenuated acetaminophen-induced mice liver injury.
Am J Transl Res, 7 (2015), pp. 309-318
[41]
Sena CM, Nunes E, Louro T, Proença T, Fernandes R, Boarder MR, et al. Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br J Pharmacol. 2008;153:894–906.
[42]
R.L. Prior, G. Cao.
Flavonoids: diet and health relationships.
Nutr Clin Care, 3 (2000), pp. 279-288
[43]
R. Saiki, M. Okazaki, S. Iwai, T. Kumai, S. Kobayashi, K. Oguchi.
Effects of pioglitazone on increases in visceral fataccumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.
J Pharmacol Sci, 105 (2007), pp. 157-167
[44]
B. Chen, H. Zhou, W. Zhao, W. Zhou, Q. Yuan, G. Yang.
Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in highfat diet induced mice.
Mol Biol Rep, 39 (2012), pp. 7981-7988
[45]
S. Payudara, K. Dan Nasofarinks, G. Tan, K. Wong, G.Q. PEArLE-WoNG, S. Yeo, et al.
In vitro cytotoxic and antiproliferative effects of Portulaca oleracea methanol extract on breast, cervical, colon and nasopharyngeal cancerous cell lines.
Sains Malays, 42 (2013), pp. 927-935
[46]
K. Musa, A. Ahmed, G. Ibrahim, O. Ojonugwa, M. Bisalla, H. Musa, et al.
Toxicity studies on the methanolic extract of Portulaca oleracea L.(Fam. Portulacaceae).
J Biol Sci, 7 (2007), pp. 1293-1295
[47]
W.K. Leung, J.C. Wu, S. Liang, L. Chan, F.K. Chan, H. Xie, et al.
Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
Am J Gastroenterol, 101 (2006), pp. 15741580
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos